An autologous stem cell transplant recipient shares her journey living with diffuse cutaneous systemic sclerosis and her decision to receive a stem cell transplant. Talaris Therapeutics Senior Scientific Advisor Dr. Suzanne Ildstad and Chief Medical Officer Dr. Nancy Krieger discuss the challenges and high unmet medical needs in this community while reviewing Talaris Therapeutics’ investigational cell therapy in FREEDOM-3, a phase 2 clinical trial being conducted in patients suffering from diffuse cutaneous systemic sclerosis.
An overview of the FREEDOM-1 travel and reimbursement policy. The study team will discuss all options with you.
An overview of the FREEDOM-2 travel and reimbursement policy. The study team will discuss all options with you.